Annalise.ai Obtains Seven New AI FDA 510(k) Clearances for Head CT and Chest X-Ray
The artificial intelligence (AI) triage and notification indications include acute subdural/epidural hematoma and acute subarachnoid hemorrhage for head computed tomography (CT) imaging.
The Food and Drug Administration (FDA) has reportedly granted a total of seven new 510(k) clearances for the use of the artificial intelligence (AI)-assisted triage modalities Annalise Triage Head CT and Annalise Triage CXR.
The new computed tomography (CT) indications for Annalise Triage Head CT include acute subdural/epidural hematoma, acute subarachnoid hemorrhage, intra-axial hemorrhage, and intraventricular hemorrhage, according to Annalise.ai, the manufacturer of Annalise Triage Head CT and Annalise Triage CXR.
The company said additional FDA clearances have increased the AI-assisted triage indications to five for Annalise Triage CXR, including detection of pneumothorax, tension pneumothorax, pleural effusion, pneumoperitoneum, and vertebral compression fracture.
Annalise.ai said the modalities utilize deep learning technology to help detect suspected pathologies and flag cases that warrant elevated priority on radiology worklists.
“AI-assisted triage is becoming increasingly important in healthcare,” noted Rick Abramson, M.D., MHCDS, FACR, the chief medical officer for Annalise.ai. “Triage solutions drive quality improvement by enabling earlier detection and intervention for our most critically ill patients. And by prioritizing the radiology worklist, these solutions also help address some of the burnout issues that have affected our specialty since the (COVID-19) pandemic.”
Newsletter
Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.
Twenty Years of CT Colonography for Colorectal Cancer Screening: What the Research Reveals
August 1st 2025Computed tomography colonography (CTC) demonstrated a 91.6 percent positive predictive value (PPV) for polyps > 6 mm, according to new research involving over 9,000 patients who underwent CTC for primary asymptomatic colorectal cancer screening.
Chest CT for Post-COVID-19 Abnormalities: Nine Takeaways from a Multi-Society Consensus Statement
August 1st 2025Developed by 21 thoracic radiologists, the new international consensus statement addresses appropriate indications, scan acquisition and keys to reporting for the use of chest CT imaging in evaluating for residual lung abnormalities from COVID-19.
Study Reveals Significant Prevalence of Abnormal PET/MRI and Dual-Energy CT Findings with Long Covid
August 1st 2025In a prospective study involving nearly 100 patients with Long Covid, 57 percent of patients had PET/MRI abnormalities and 90 percent of the cohort had abnormalities on dual-energy CT scans.
